VM
NBIX icon

VHCP Management’s Neurocrine Biosciences NBIX Stock Holding History

VHCP Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-303,503
Closed -$4.76M – 21
2014
Q3 		$4.76M Hold
303,503
– – 2.14% 11
2014
Q2 		$4.5M Hold
303,503
– – 2.41% 13
2014
Q1 		$4.89M Sell
303,503
-391,400
-56% -$6.69M 2.54% 12
2013
Q4 		$6.49M Sell
694,903
-576,400
-45% -$5.62M 3.49% 12
2013
Q3 		$14.4M Sell
1,271,303
-693,370
-35% -$9.53M 7.95% 7
2013
Q2 		$26.3M Buy
+1,964,673
New +$24.1M 19.52% 1

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

VHCP Management's NBIX Position: Q4 2014 in Review

VHCP Management sold out of Neurocrine Biosciences (NBIX) in Q4 2014, closing a stake of 303,503 shares — an estimated $4.76M sold.

VHCP Management first reported a position in NBIX in Q2 2013 and held it in 6 quarters. The position peaked at $26.3M in Q2 2013. 133 funds tracked by Wall St. Rank hold NBIX as of Q4 2014.

  • VHCP Management reported no remaining Neurocrine Biosciences position as of Q4 2014 after selling out during the quarter.
  • VHCP Management sold 303,503 Neurocrine Biosciences shares in Q4 2014, an estimated $4.76M.
  • VHCP Management first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 6 quarters.
  • VHCP Management's Neurocrine Biosciences position peaked at $26.3M in Q2 2013.
  • 133 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2014.

Based on VHCP Management's 13F filing for Q4 2014, filed 13 Feb 2015.